Format
Sort by

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 128

1.

A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.

Lissoni P, Ardizzoia A, Barni S, Paolorossi F, Tancini G, Meregalli S, Esposti D, Zubelewicz B, Braczowski R.

Oncol Rep. 1995 Sep;2(5):871-3.

PMID:
21597833
2.

Melatonin modulation of estrogen-receptor expression in mcf-7 human breast-cancer cells.

Molis T, Walters M, Hill S.

Int J Oncol. 1993 Oct;3(4):687-94.

PMID:
21573419
3.

The fate of melatonin in animals.

KOPIN IJ, PARE CM, AXELROD J, WEISSBACH H.

J Biol Chem. 1961 Nov;236:3072-5. No abstract available.

4.

[Experiments in the postoperative therapy of cancer with pineal body extracts].

HOFSTAETTER R.

Krebsarzt. 1959 Aug;14:307-16. German. No abstract available.

PMID:
14402468
5.

Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors.

HUGGINS C, BRIZIARELLI G, SUTTON H Jr.

J Exp Med. 1959 Jan 1;109(1):25-42.

6.

Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice.

Collins A, Yuan L, Kiefer TL, Cheng Q, Lai L, Hill SM.

Cancer Lett. 2003 Jan 10;189(1):49-57.

PMID:
12445677
7.

The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo.

Fu L, Pelicano H, Liu J, Huang P, Lee C.

Cell. 2002 Oct 4;111(1):41-50. Erratum in: Cell 2002 Dec 27;111(7):1055.

8.

Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue.

Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T, Asch HL.

Am J Clin Pathol. 2002 Sep;118(3):451-8.

9.

Does light cause internal cancers? The problem and challenge of an ubiquitous exposure.

Erren TC.

Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:61-70. Review.

PMID:
12163851
10.

Melatonin in clinical oncology.

Bartsch C, Bartsch H, Karasek M.

Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:30-8. Review.

PMID:
12019349
11.

Host circadian clock as a control point in tumor progression.

Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, Claustrat B, Hastings MH, Lévi F.

J Natl Cancer Inst. 2002 May 1;94(9):690-7.

12.
13.

Involvement of the mt1 melatonin receptor in human breast cancer.

Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L, Hill SM.

Cancer Lett. 2002 May 28;179(2):141-50.

PMID:
11888668
14.

Melatonin inhibits estrogen receptor transactivation and cAMP levels in breast cancer cells.

Kiefer T, Ram PT, Yuan L, Hill SM.

Breast Cancer Res Treat. 2002 Jan;71(1):37-45.

PMID:
11859872
15.

Chronic exposure to a GSM-like signal (mobile phone) does not stimulate the development of DMBA-induced mammary tumors in rats: results of three consecutive studies.

Bartsch H, Bartsch C, Seebald E, Deerberg F, Dietz K, Vollrath L, Mecke D.

Radiat Res. 2002 Feb;157(2):183-90. Review.

PMID:
11835682
16.

Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells.

Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniewski A, Wortsman J.

FEBS Lett. 2002 Jan 30;511(1-3):102-6.

17.

Epigenetics: unforeseen regulators in cancer.

Muyrers-Chen I, Paro R.

Biochim Biophys Acta. 2001 Nov 30;1552(1):15-26. Review.

PMID:
11781112
18.

Antihypertensive therapy and cancer risk.

Felmeden DC, Lip GY.

Drug Saf. 2001;24(10):727-39. Review.

PMID:
11676301
19.

Rotating night shifts and risk of breast cancer in women participating in the nurses' health study.

Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA.

J Natl Cancer Inst. 2001 Oct 17;93(20):1563-8.

20.

Seasonal rhythms of 6-sulphatoxymelatonin (aMT6s) excretion in female rats are abolished by growth of malignant tumors.

Bartsch H, Bartsch C, Deerberg F, Mecke D.

J Pineal Res. 2001 Aug;31(1):57-61.

PMID:
11485005
Items per page

Supplemental Content

Support Center